Woodline Partners LP Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Woodline Partners LP grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 20.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,202,466 shares of the company's stock after purchasing an additional 201,573 shares during the quarter. Woodline Partners LP owned about 1.90% of Vera Therapeutics worth $50,852,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in VERA. Barclays PLC boosted its position in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after purchasing an additional 41,394 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after buying an additional 10,916 shares in the last quarter. KBC Group NV lifted its holdings in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after buying an additional 1,387 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vera Therapeutics by 27.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company's stock worth $568,000 after buying an additional 2,882 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Vera Therapeutics by 82.0% in the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after buying an additional 366,763 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target on the stock. HC Wainwright initiated coverage on shares of Vera Therapeutics in a report on Monday, May 5th. They issued a "buy" rating and a $75.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Guggenheim increased their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average price target of $63.33.

Vera Therapeutics Price Performance

VERA traded up $0.01 on Friday, reaching $19.64. The company had a trading volume of 1,064,297 shares, compared to its average volume of 782,385. The business has a 50 day simple moving average of $22.74 and a 200 day simple moving average of $33.10. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -7.52 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter last year, the firm earned ($0.56) EPS. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.